Lenalidomid Zentiva

Lenalidomide, the active ingredient in Lenalidomid Zentiva, is an immunomodulatory drug presented as an oral tablet for oral use. It is indicated for the treatment of multiple myeloma and myelodysplastic syndromes in adult patients. The compound modulates immune cell activity, inhibits angiogenesis, and promotes apoptosis of malignant cells, contributing to disease control.

GNH USA supplies Lenalidomid Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide with a focus on quality assurance and regulatory compliance.

Lenalidomid Zentiva is an immunomodulatory antineoplastic that acts on malignant plasma cells and dysplastic hematopoietic clones. - Multiple myeloma: improves progression‑free survival and overall response rates in adult patients with relapsed or refractory disease. - Myelodysplastic syndromes (with del(5q) cytogenetic abnormality): reduces transfusion dependence and induces cytogenetic remission in adult patients.

Lenalidomid Zentiva may be associated with a range of adverse reactions, which are categorized by frequency and severity. Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: low platelet count leading to easy bruising. - Diarrhea: loose stools that may cause dehydration. - Nausea: feeling of sickness that may lead to vomiting. Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism: blood clots that can be life‑threatening. - Secondary primary malignancies: emergence of new cancers during therapy. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating Lenalidomid Zentiva, healthcare professionals should consider several precautionary measures to minimize risks. - Pregnancy risk: drug may cause fetal harm; avoid use in pregnant women and ensure effective contraception. - Thromboembolic risk: assess patient history and consider prophylactic anticoagulation when risk factors are present. - Renal impairment: adjust monitoring and dosage in patients with reduced kidney function. - Hepatic impairment: evaluate liver function and monitor for increased toxicity. - Immunosuppression: monitor blood counts regularly to detect neutropenia or thrombocytopenia. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Lenalidomid Zentiva can interact with other medicines, altering its efficacy or safety profile. Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): increased risk of thromboembolic events when combined. Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., cyclosporine, tacrolimus): may enhance immunosuppression and infection risk. - Vaccines (live attenuated): reduced efficacy; avoid concurrent administration. - P-glycoprotein substrates (e.g., digoxin): possible altered plasma levels requiring monitoring.